MedPath

Watermelon Supplementation and Arterial Stiffness

Phase 1
Completed
Conditions
Hypertension
Interventions
Dietary Supplement: Watermelon Extract
Registration Number
NCT01185041
Lead Sponsor
Florida State University
Brief Summary

Increased abdominal obesity (waist circumference) and systolic blood pressure (BP) are main risk factors for the metabolic syndrome. Approximately 60% of adults in the United States are prehypertensive or hypertensive. Hypertension has been associated with abnormal endothelial and autonomic function, the two main mechanisms of BP regulation. Endothelial dysfunction, as a result of reduced NO (a vasodilator), and increased sympathetic nervous system activity contribute to arterial stiffness by enhancing the vasomotor tone. Because BP variations are sensed by baroreceptors in the wall of large arteries, increased stiffness of arteries may attenuate the control of BP by the autonomic nervous system leading to hypertension. High production of proinflammatory cytokines and low adiponectin (vascular protective molecule), are considered the underlying mechanisms leading to endothelial dysfunction and arterial stiffness. The recommended intervention for controlling BP in overweight/obese individuals with pre- and stage 1- hypertension is lifestyle modifications and not drug therapy. Among the dietary regimens that are reported to reduce BP is L-arginine, the substrate for endothelial NO production. Recently, oral L-citrulline has been shown to be more effective than L-arginine in improving circulating NO levels because is not affected by enzymatic degradation. Watermelon, the leading US melon crop, is one of the few natural foods rich in L-citrulline which is efficiently transformed to arginine in humans. The investigators long-term goal is to provide feasible and effective dietary ways to reduce cardiovascular risk factors in individuals with high abdominal fat and BP. The overall objective of this study is to bring forth evidence that watermelon supplementation will reduce BP and cardiovascular risk factors such as arterial stiffness, autonomic dysfunction and endothelial dysfunction. The investigators postulate that watermelon supplementation will reduce BP and arterial stiffness by enhancing endothelial function and reducing vascular inflammation. The findings of this study will provide a foundation for disseminating feasible, safe approaches for preventing and combating obesity-related hypertension at its early stage which does not require drug therapy.

Detailed Description

The purpose of the study is to examine the effect of 12 weeks of L-citrulline/L-arginine in the form of watermelon supplementation on arterial function and autonomic neural control of the heart rate and blood pressure in older overweight/obese men and women with pre- and stage 1- hypertension. The specific aims of the study are:

1. To investigate the extent to which daily consumption of watermelon supplementation containing L-citrulline/L-arginine (4/2 g) will reduce BP and arterial stiffness. This aim will examine the working hypothesis that watermelon supplementation will reduce BP and improve arterial function. This aim will be tested by measuring brachial and central (aortic and carotid) BP at rest and during physiological stress (head-up tilt test and cold pressor test), and by evaluating arterial stiffness using pulse wave velocity of the aorta and legs as primary variables.

2. To determine the effect of watermelon supplementation on endothelial function. There is evidence that watermelon improves endothelial function in rats. Hence, we postulate that watermelon in part exerts its vascular protective effects by modulating indices of endothelial function. This aim will be tested by measuring flow-mediated dilation using vascular ultrasound and circulating levels of vasodilators, vasoconstrictors, and markers of vascular inflammation (adiponectin, leptin, endothelin-1, angiotensin II, prostaglandin F2α, sVCAM-1, sICAM-1, and 8-isoprostane).

3. To determine whether watermelon supplementation will improve the autonomic control of BP and heart rate in individuals with high abdominal obesity and BP. There is evidence that food high in L-arginine improves baroreflex sensitivity (BRS) in individuals with pre-hypertension. This aim will examine the working hypothesis that watermelon will improve cardiovascular autonomic control of BP by measuring heart rate variability, BP variability and BRS at rest and during physiological stress as secondary variables.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
20
Inclusion Criteria
  • Thirty men and women 45-70 years of age
  • BP between 120-159/80-99 mmHg
  • Waist circumference >102 cm in men and > 80 cm in women
Exclusion Criteria
  • BP >160/100 mmHg
  • Asthma
  • Glaucoma
  • Herpes simplex
  • Uncontrolled diabetes
  • Neurological disease
  • Cardiovascular disease
  • Inflammatory disease
  • Kidney disease
  • Hormone replacement therapy (HRT)
  • Amino acid/vitamin supplementation\
  • Corticosteroids or non-steroidal anti-inflammatory drugs
  • Any drug known to affect BP or heart rate
  • Glycemic control drugs
  • Lipids reducing drugs
  • Participants should not consume > 12 alcoholic drink/week
  • Smokers
  • Regular Exercisers (= 1.5 hour/week).

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Arm && Interventions
GroupInterventionDescription
MaltodextrinWatermelon Extract6g/day of placebo (maltodextrin)
WatermelonWatermelon Extract(6g per day)containing L-citrulline/L-arginine (4/2 g)
Primary Outcome Measures
NameTimeMethod
Blood Pressure12 weeks

By measuring brachial and central (aortic and carotid) BP at rest and during physiological stress (head-up tilt test and cold pressor test)

Secondary Outcome Measures
NameTimeMethod
Arterial Stiffness12 weeks

Using pulse wave velocity of the aorta and legs.

Endothelial function12 weeks

By measuring flow-mediated dilation using vascular ultrasound and circulating levels of vasodilators, vasoconstrictors, and markers of vascular inflammation (adiponectin, leptin, endothelin-1, angiotensin II, prostaglandin F2α, sVCAM-1, sICAM-1, and 8-isoprostane).

Autonomic control of BP12 weeks

By measuring BP variability and BRS at rest and during physiological stress

Autonomic control of heart rate12 weeks

By measuring heart rate variability at rest and during physiological stress

Trial Locations

Locations (1)

Cardiovascular Physiology Laboratory

🇺🇸

Tallahassee, Florida, United States

© Copyright 2025. All Rights Reserved by MedPath